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Objective: Despite dramatic increases in the misuse
of prescription opioids, the extent to which their
intravenous injection places drug users at risk of
acquiring hepatitis C virus (HCV) remains unclear.
We sought to compare risk of HCV acquisition from
injection of prescription opioids to that from other
street drugs among high-risk street youth.
Design: Prospective cohort study.
Setting: Vancouver, British Columbia, Canada from
September 2005 to November 2011.
Participants: The At-Risk Youth Study (ARYS) is a
prospective cohort of drug-using adolescents and
young adults aged 14–26 years. Participants were
recruited through street-based outreach and snowball
sampling.
Primary outcome measure: HCV antibody
seroconversion, measured every 6 months during
follow-up. Risk for seroconversion from injection of
prescription opioids was compared with injection of
other street drugs of misuse, including heroin, cocaine
or crystal methamphetamine, using Cox proportional
hazards regression controlling for age, gender and
syringe sharing.
Results: Baseline HCV seropositivity was 10.6%.
Among 512 HCV-seronegative youth contributing 860.2
person-years of follow-up, 56 (10.9%) seroconverted,
resulting in an incidence density of 6.5/100 person-
years. In bivariate analyses, prescription opioid
injection (HR=3.48; 95% CI 1.57 to 7.70) predicted
HCV seroconversion. However, in multivariate
modelling, only injection of heroin (adjusted HR=4.56;
95% CI 2.39 to 8.70), cocaine (adjusted HR=1.88;
95% CI 1.00 to 3.54) and crystal methamphetamine
(adjusted HR=2.91; 95% CI 1.57 to 5.38) remained
independently associated with HCV seroconversion,
whereas injection of prescription opioids did not
(adjusted HR=0.94; 95% CI 0.40 to 2.21).
Conclusions: Although misuse of prescription opioids
is on the rise, traditional street drugs still posed the
greatest threat of HCV transmission in this setting.
Nonetheless, the high prevalence and incidence of HCV
among Canadian street youth underscore the need for
evidence-based drug prevention, treatment and harm
reduction interventions targeting this vulnerable
population.
INTRODUCTION
Hepatitis C virus (HCV) infection is a
leading cause of morbidity and mortality
worldwide.
1–3 While the incidence of HCV
may be decreasing in some age groups, infec-
tion rates appear to be increasing among ado-
lescents and young adults.
4 Street youth—that
is, youth who spend all or part of their time
working or living on the street
56 —represent
a marginalised and stigmatised population at
Strengths and limitations of this study
▪ A strength of this prospective cohort study is
that it followed street youth, a marginalised and
difficult-to-reach population with a high preva-
lence of injection drug use and blood-borne
infection, including HIV and hepatitis C virus
(HCV).
▪ An additional strength is that it is among the first
studies to examine the association between
injection of prescription opioids (including, eg,
oxycodone and morphine) and acquisition of
HCV; it is not well understood how the risk for
acquiring HCV from injecting prescription
opioids compares to that from injection of more
traditionally studied street drugs, such as heroin,
cocaine and crystal methamphetamine.
▪ The study’s findings demonstrate an elevated
risk for HCV seroconversion in relation to heroin,
cocaine and crystal methamphetamine injection,
but not prescription opioid injection after adjust-
ment for covariates; however, the relatively small
number of youth injecting prescription opioids
may have limited detection of marginal risk
differences.
▪ Since youth in the study were recruited by snow-
ball sampling, results are not obtained from a
truly random sample, but characteristics of the
cohort are comparable to those from studies of
street youth conducted elsewhere.
▪ This study demonstrates novel findings that
should prompt further study of risk for blood-
borne infection among drug-injecting youth
populations.
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lence of injection drug use.
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The emergence of elevated rates of HCV among street
youth coincides with important changes in patterns of
youth substance use. In recent years, misuse of prescrip-
tion opioids such as morphine, oxycodone and hydroco-
done has emerged as a public health emergency.
9
Although injection of illicit drugs is known to place
users at high risk of blood-borne infection,
10 11 the
abundance of studies until now has focused on trad-
itional street drugs, such as heroin and cocaine, rather
than prescription opioids.
12
This constitutes a serious gap in our understanding of
HCV epidemiology given that, in many jurisdictions,
overdose mortality attributed to prescription opioid use
has surpassed that attributed to the use of heroin and
cocaine combined.
13 The prevalence of non-medical
prescription opioid use is increasing in the general ado-
lescent population,
14 with approximately 8–10% of high
school students in the USA reporting past-year use.
15
Many prescription opioid formulations are readily
injected,
16 17 but despite their widespread availability,
there is a paucity of epidemiological data examining this
practice or its risk for disease transmission.
18
At this time, it remains unclear whether heroin injec-
tors and prescription opioid injectors represent overlap-
ping or distinct subpopulations of injection drug users.
19
There is evidence that some users follow a trajectory from
initially using prescription opioids to ultimately using
heroin, since in some settings heroin is less expensive
and more potent and available.
16 On the other hand,
there may be a sizeable subgroup of users who inject pre-
scription opioids to the exclusion of heroin and other
drugs.
20 Nonetheless, there is reason to believe that
certain injection practices associated with heroin as com-
pared with prescription opioids may place users at differ-
ential risk for infectious disease transmission.
17 20
Understanding how the injection of prescription
opioids may place users at risk for acquiring HCV is
imperative, given that injection drug users represent the
population at greatest risk for HCV infection in North
America,
21 22 and that mortality from HCV has
increased to the extent that it recently surpassed that
from HIV in the USA.
2 We conducted the present study
of HCV acquisition in Vancouver, Canada among a pro-
spective cohort of street youth, a population including a
high proportion of Aboriginal youth who may be at ele-
vated risk for blood-borne infection.
23 Our study object-
ive was to examine the contribution of injection of
prescription opioids and that of traditional street drugs
of misuse to the risk for HCV seroconversion.
METHODS
The At-Risk Youth Study (ARYS) is a cohort of
street-involved youth in Vancouver, Canada.
24 Inclusion
criteria for enrolment included age 14–26 years and use
of an illicit drug other than marijuana during the month
prior to enrolment. Recruitment relied on extensive
daytime and night-time street-based outreach and snow-
ball sampling, and was systematically conducted in the
parks, streets and alleyways of Vancouver where street
youth are known to congregate. Although no inclusion
criterion explicitly required a minimum amount of time
on the street to qualify for the study, in practice the street-
based recruitment resulted in a sample of youth who
spent substantial time on the street, a large proportion of
whom were homeless.
25 Full study details were disclosed
to participants and informed consent was obtained. At
baseline and every 6 months thereafter, participants com-
pleted an interview and underwent HCVantibody testing.
Participants were remunerated $C20 per visit.
Additionally, a $C5 incentive was provided to youth
3 months after their baseline interview to return to the
study site to update their contact information in an
attempt to improve study follow-up.
We compared HCV prevalence at recruitment and
subsequent HCV incidence among youth according to
the recent (ie, during the preceding 6 months) injection
of a prescription opioid and recent injection of heroin,
cocaine and crystal methamphetamine. Prescription
opioids were broadly deﬁned to include morphine, oxy-
codone, hydromorphone, meperidine, fentanyl or
methadone. The exact question used was, “In the last
6 months, when you were using, which of the following
drugs did you inject and how often?”, with possible
answers including, “Less than once per month/One to
three times per month/About once per week/Two or
three times per week/At least daily”. Using this question,
each of the prescription opioids listed above was indi-
vidually and sequentially probed. We also examined pat-
terns of non-injection use of prescription opioids in the
sample. All ARYS participants were included in the base-
line HCV prevalence analyses. Participants who were
HCV antibody negative at baseline and returned for ≥1
follow-up visit were included in the incidence analyses.
We also examined an additional array of covariates
including: gender, age (as a continuous variable),
Aboriginal ancestry, high school education (having com-
pleted or currently enrolled in high school), self-
reported gay/lesbian/bisexual orientation, recent home-
lessness, recent incarceration, recent sharing of injection
syringes, recent inconsistent condom use (vaginal or
anal penetrative sex without condom use 100% of the
time) and recent sex work (having traded sex for
money, drugs, shelter or gifts). In the baseline preva-
lence analysis, all participants were compared according
to HCV serostatus through χ
2 (for categorical variables)
and Wilcoxon rank-sum tests (for continuous variables).
Similar statistics were also calculated to compare
drug-related behaviours between Aboriginal and
non-Aboriginal youth.
23
We then conducted the incidence analysis with the
outcome of time to HCV seroconversion, limiting the
sample to those who were HCV antibody negative at
baseline and returned for ≥1 follow-up visit. Youth with
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compared in univariate analyses to consider differences
between these two subgroups.
26 We subsequently used
Kaplan-Meier methods to plot the cumulative incidence
of HCV seroconversion as a function of time. All
follow-up data were included, even if a participant had
missed an intervening follow-up appointment.
We also used Cox proportional hazards regression to
determine unadjusted and adjusted HR for HCV sero-
conversion for the range of drug use-related variables
and other covariates listed above. An interaction term
between heroin and prescription opioid injection was
also tested. The time of seroconversion was estimated as
the midpoint of the date of the last known seronegativity
and of that of the ﬁrst seropositivity.
27–29 Independent
variables were time-updated in regression models if they
referred to non-ﬁxed characteristics or behaviours in the
preceding 6 months. In the event of differential
follow-up duration among participants recruited earlier
in the study period compared to later in the study
period, we examined the prevalence of prescription
opioid injection and heroin in the ﬁrst 2 years of study
and in the past 2 years of study to determine whether
these behaviours were becoming more common with
time.
14 We also examined prevalence of cocaine and
crystal methamphetamine over the course of the study.
We sought to directly compare the risk for HCV serocon-
version from injection of heroin and other traditional
drugs of misuse to that from injection of prescription
opioids,
17 20 and created three multivariable models to do
so. The ﬁrst model included recent heroin injection but
not recent prescription opioid injection; the second,
recent prescription opioid injection but not recent heroin
injection; and the third, recent heroin injection and
recent prescription opioid injection. To adjust for poten-
tial confounders, age and gender were included in multi-
variable models as well as covariates signiﬁcant at p<0.05
in the initial bivariate Cox regression analyses of time to
HCV seroconversion. Finally, as a subanalysis, we restricted
the sample to drug-injecting youth and examined bivariate
associations between injection of prescription opioids,
heroin, cocaine and crystal methamphetamine and HCV
seroconversion. We also repeated the third multivariate
model using this subsample.
Analyses were conducted with SAS V.9.1 (SAS Institute,
Inc, Cary, North Carolina, USA). All p values were two-
sided and tests were considered signiﬁcant at p<0.05.
Adjustments were not made for multiple comparisons
given that this was a single-outcome observational study.
RESULTS
From September 2005 to November 2011, 940 youth
were recruited into the ARYS cohort and completed
baseline HCV antibody testing. One hundred youth
(10.6%) were HCV-seropositive at study enrolment.
Table 1 shows baseline characteristics and recent (ie, in
the 6 months preceding study enrolment) drug-related
and sexual risk behaviours according to HCV serostatus.
The cohort spent a median of 12 h on the street per day
Table 1 Baseline characteristics of 940 street youth, according to the hepatitis C virus (HCV) serostatus at study enrolment:





Yes (%) (n=100) No (%) (n=840) OR (95% CI) p Value
Sociodemographic factors
Male gender 654 (69.6) 63 (63.0) 591 (70.4) 0.72 (0.47 to 1.11) 0.131
Mean age (SD)* 21.7 (2.7) 23.4 (2.5) 21.5 (2.7) 1.34 (1.23 to 1.47) <0.001
Aboriginal ancestry 224 (23.8) 30 (30.0) 194 (23.1) 1.43 (0.90 to 2.25) 0.126
High school education† 415 (64.8) 35 (35.0) 380 (45.2) 0.65 (0.42 to 1.00) 0.051
Gay/lesbian/bisexual 151 (16.1) 22 (22.0) 129 (15.4) 0.64 (0.39 to 1.07) 0.087
Recent homelessness‡ 348 (37.0) 54 (54.0) 294 (35.0) 2.18 (1.44 to 3.31) <0.001
Recent incarceration‡ 176 (18.7) 26 (26.0) 150 (17.9) 1.62 (1.00 to 2.61) 0.048
Substance use-related behaviours
Mean years injecting (SD)§ 4.3 (3.2) 4.0 (3.3) 4.6 (3.2) 0.94 (0.82 to 1.07) 0.350
Non-injection prescription opioid use‡ 90 (9.6) 12 (12.0) 78 (9.3) 1.33 (0.70 to 2.54) 0.383
Prescription opioid injection‡ 64 (6.8) 28 (28.0) 36 (4.3) 8.69 (5.01 to 15.1) <0.001
Heroin injection‡ 191 (20.3) 66 (66.0) 125 (14.9) 11.1 (7.04 to 17.5) <0.001
Cocaine injection‡ 93 (9.9) 31 (31.0) 62 (7.4) 5.54 (3.43 to 9.26) <0.001
Crystal methamphetamine injection‡ 154 (16.4) 50 (50.0) 104 (12.4) 7.08 (4.55 to 11.0) <0.001
Syringe sharing‡ 56 (6.0) 18 (18.0) 38 (4.5) 4.63 (2.53 to 8.48) <0.001
Sexual risk behaviours
Inconsistent condom use‡ 433 (46.1) 40 (40.0) 393 (46.8) 0.76 (0.50 to 1.16) 0.198
Sex work‡ 65 (6.9) 14 (14.0) 51 (6.1) 2.52 (1.34 to 4.74) 0.003
*OR calculated per year older.
†Prior completion of or current enrolment in high school.
‡During the 6 months preceding study enrolment.
§Includes only actively injecting youth.
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of the sample. Aboriginal and non-Aboriginal youth did
not differ with regard to recent non-injection prescrip-
tion opioid use, recent injection of prescription opioids,
heroin, cocaine or crystal methamphetamine or recent
syringe sharing (p>0.05 for all). As shown, baseline HCV
seropositivity was associated with older age, recent home-
lessness, recent incarceration, recent injection of pre-
scription opioids, heroin, cocaine and crystal
methamphetamine, recent syringe sharing and recent
sex work. Recent injection of prescription opioids and of
heroin were correlated (p<0.05).
Of the 840 youth who were HCV antibody negative at
baseline, 512 (60.9%) had at least one follow-up visit
and provided blood samples for HCV antibody testing.
Among these 512 youth, 151 (29.5%) were female and
135 (67.2%) identiﬁed as Aboriginal. The mean age was
21.7 (SD 2.6) years. Compared with the 328 (29.1%)
participants who were HCV antibody negative at baseline
and did not provide follow-up data, the 512 participants
included in subsequent incidence analyses tended to be
older (p<0.05), but did not differ at baseline in terms of
gender, Aboriginal ancestry, recent incarceration, recent
sex work, recent injection of prescription opioids,
heroin, cocaine or crystal methamphetamine or recent
syringe sharing.
At study enrolment, 166 (32.4%) of the 512 youth
included in the incidence analysis reported prior drug
injection. Compared with those who had not previously
injected, those who had injected were more likely to be
older (p<0.05), but otherwise did not differ by gender,
Aboriginal ancestry, recent incarceration or recent sex
work. Of the 166 youth who had previously injected, 56
(33.7%) reported recently having injected two or more
drugs among prescription opioids, heroin, cocaine and
crystal methamphetamine, and 11 (6.6%) reported
having injected three or more of these drugs.
During the follow-up period (median follow-up,
18.5 months; median number of follow-up visits after
baseline visit, 2 visits; total follow-up, 860.2 person-years),
there were 56 (10.9%) HCV seroconversions, resulting
in an incidence density of 6.5/100 person-years. As
might be expected, median follow-up was longer in the
earlier years of study enrolment (22 months in the ﬁrst
2 years of enrolment vs 17 months in the ﬁnal 2 years;
p<0.001). The median number of missed visits during
follow-up was 1 visit. Individuals lost to follow-up were
censored at the time of their last visit.
Over the study period, the prevalence of prescription
opioid injection remained relatively unchanged (4.2%
of the entire sample in the ﬁrst 2 years of enrolment vs
4.4% in the past 2 years) as did that of heroin injection
(13.5% vs 11.8%). Similarly, there was very little change
in the prevalence of cocaine injection (12.2% of the
entire sample in the ﬁrst 2 years of enrolment vs 10.0%
in the past 2 years) and crystal methamphetamine injec-
tion (18.0% vs 16.8%). At baseline, recent heroin injec-
tors and recent prescription opioid injectors did not
differ in terms of age (mean, 21.8 vs 22.3 years, respect-
ively; p=0.524), gender (65.5% vs 72.2% male; p=0.202),
ethnicity (20.7% Aboriginal vs 16.7% other; p=0.256),
age of initiation of injection drug use (mean, 17.7 vs
18.7 years; p=0.271) or in total number of years of inject-
ing (mean, 4.1 vs 3.6 years; p=0.567).
Figure 1A shows the Kaplan-Meier cumulative inci-
dence of HCV seroconversion according to heroin injec-
tion in the entire sample and ﬁgure 1B shows the
cumulative incidence according to heroin injection with
the sample restricted to drug-injecting youth only. In
both cases, heroin injectors had a markedly elevated risk
of HCV seroconversion in comparison to others in the
sample, including prescription opioid injectors (full
data available from the corresponding author). The
crude incidence density of HCV seroconversion among
heroin-injecting youth was 20.8/100 person-years, and
among prescription opioid-injecting youth it was 21.4/
100 person-years. The mean number of visits prior to
seroconversion did not differ between heroin and pre-
scription opioid injectors (p>0.05).
Table 2 displays the results of the unadjusted and
adjusted Cox proportional hazard regression analyses of
the time to detected HCV seroconversion according to
demographic characteristics and risk behaviours. As
shown, HCV seroconversion was signiﬁcantly associated
with female gender, prescription opioid injection,
heroin injection, cocaine injection, crystal metham-
phetamine injection and syringe sharing in unadjusted
analyses. Age was not associated with HCV seroconver-
sion. Additional variables not listed in the table that
were not signiﬁcantly associated with HCV seroconver-
sion included Aboriginal ancestry (unadjusted HR=0.88;
95% CI 0.49 to 1.59; p=0.662), recent incarceration
(HR=1.25; 95% CI 0.67 to 2.32; p=0.482), recent incon-
sistent condom use (unadjusted HR=0.90; 95% CI 0.52
to 1.55; p=0.703) and recent sex work (unadjusted
HR=0.91; 95% CI 0.28 to 2.90; p=0.869). Additionally,
the interaction term between heroin and prescription
opioid injection was not signiﬁcant (p>0.05).
The three multivariable models examining the relative
effects of prescription opioid injection and heroin injec-
tion all were adjusted for gender and age, as well as for
variables signiﬁcant at p<0.05 in unadjusted Cox regres-
sion analyses (cocaine injection, crystal methampheta-
mine injection and syringe sharing). In the model
including all covariates except prescription opioid injec-
tion, heroin injection remained signiﬁcantly associated
with HCV seroconversion (model 1), whereas prescrip-
tion opioid injection did not retain signiﬁcance in the
model including all covariates except heroin (model 2).
When heroin injection and prescription opioid injection
were included, a combined model, heroin injection, but
not prescription opioid injection, retained statistical sig-
niﬁcance (model 3).
When the sample was restricted to only drug-injecting
youth (n=166), prescription opioid injection was not
associated with HCV seroconversion in bivariate analyses
4 Hadland SE, et al. BMJ Open 2014;4:e005419. doi:10.1136/bmjopen-2014-005419
Open Access(unadjusted HR=1.27; 95% CI 0.57 to 2.84; p=0.555).
Heroin injection was associated with HCV seroconver-
sion in this subsample (unadjusted HR=2.93; 95% CI
1.77 to 6.13; p<0.001), as was cocaine injection
(unadjusted HR=2.02; 95% CI 1.11 to 3.68; p=0.021),
but not crystal methamphetamine injection (unadjusted
HR=4.52; 95% CI 0.61 to 33.3; p=0.136). Syringe sharing
was also associated with HCV seroconversion
(unadjusted HR=2.93; 95% CI 1.48 to 5.79; p=0.002).
When model 3 was rerun using this subsample, variables
remaining signiﬁcantly associated with HCV seroconver-
sion included heroin injection (adjusted HR=2.79; 95%
CI 1.46 to 5.34; p=0.002) and syringe sharing (adjusted
HR=2.47; 95% CI 1.22 to 4.98; p=0.012), but not pre-
scription opioid injection (adjusted HR=0.60; 95% CI
0.25 to 1.47; p=0.268), cocaine injection (adjusted
HR=1.83; 95% CI 0.98 to 3.40; p=0.057) or crystal meth-
amphetamine injection (adjusted HR=4.13; 95% CI 0.47
to 36.0; p=0.199).
DISCUSSION
In this longitudinal study, we observed a high prevalence
of HCV seropositivity among adolescents and young
adults on the street, with more than 1 in 10 youth
infected with HCV at baseline, as well as high incidence
HCV acquisition during follow-up. We observed that
injections of heroin, cocaine and crystal methampheta-
mine were all strongly associated with risk HCV serocon-
version following adjustment for potential confounders.
Injection of prescription opioids, in contrast, was not
independently associated with HCV seroconversion in
adjusted models, although it was associated with HCV
seropositivity at baseline and with HCV seroconversion
in unadjusted analyses. Taken together, these ﬁndings
highlight street youth as a population that should
remain a critical focus for evidence-based drug prevent-
ive and treatment services to prevent a worsening HCV
epidemic.
Although misuse of prescription opioids is on the rise
in North America,
15 and although they are readily
injected,
16 17 we did not observe excess risk for HCV
seroconversion from injection of prescription opioids
among Vancouver street youth after controlling for
other factors. There are several plausible explanations
for the null ﬁnding in this setting. First, we acknowledge
that despite a large sample of drug-using youth, the pro-
portion of participants in the cohort who engaged in
prescription opioid injection was relatively small and
may have somewhat limited detection of marginal risk
differences. Prescription opioid injection was signiﬁ-
cantly associated with HCV seroconversion in univariate
incidence analyses, suggesting increased risk from this
behaviour. However, in the setting of polysubstance use,
which was common in this setting, the contribution of
prescription opioid injection to risk for HCV seroconver-
sion appears to be relatively less important than that of
traditional drugs of misuse including heroin, cocaine
and crystal methamphetamine. Indeed, since injections
of prescription opioids and of heroin were correlated in
our sample, our results are consistent with those of
other reports that many heroin injectors also inject pre-
scription opioids when they cannot easily locate heroin
or cannot afford it.
17 We recommend that future studies
actively recruit prescription opioid-injecting youth in
order to improve estimates of risk for HCV.
Second, as has been described elsewhere, populations
of drug users often show great heterogeneity, with sub-
populations exhibiting widely varying risk for blood-
borne disease.
19 In Vancouver, youth who inject
Figure 1 (A) Cumulative incidence of hepatitis C infection
among (A) 512 drug-using youth, by injection heroin use and
(B) drug-injecting youth by heroin use: At-Risk Youth Study
(ARYS), Vancouver, Canada, 2005–2010.
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inject other drugs, may represent a distinct subpopula-
tion from other higher risk youth who inject heroin,
cocaine or crystal methamphetamine but not prescrip-
tion opioids, as has been observed in other settings.
20 It
is possible that prescription opioid-injecting youth may
not be as entrenched in the local drug scene
30 and, as a
result, may not associate as frequently with
HCV-seropositive drug users. Similarly, youth who inject
prescription opioids may have received different prevent-
ive messaging regarding safe injection practices, or have
better access to harm reduction services. A better under-
standing of the risk environment for prescription opioid
users will prove important for preventing transmission of
HCV in this high-risk population.
Although prescription opioid injection was not inde-
pendently associated with risk for HCV seroconversion,
more traditional risk factors, including injection of
heroin, cocaine, and crystal methamphetamine, were
strongly and independently associated with HCV acquisi-
tion in this setting. These ﬁndings are consistent with
those from previous youth studies.
83 1 –33 It is well estab-
lished that HCV is spread when drug users share injec-
tion paraphernalia.
34 35 Interestingly, although syringe
sharing was associated with HCV seroconversion in the
ARYS sample, it did not fully explain the risk for HCV
associated with injection of heroin, cocaine and crystal
methamphetamine in ﬁnal multivariable models. A pos-
sible explanation may be that youth under-reported
syringe sharing, which might be perceived as a stigma-
tised behaviour. The result of such socially desirable
reporting could be the incomplete effect sizes observed
in our statistical models.
36 37 Nonetheless, attempts to
prevent the spread of HCV among at-risk youth will
require careful attention to factors that interfere with
safe injection practices, including peer dynamics and
chaotic injection environments.
38 39
The excess risk for HCV among street youth necessi-
tates evidence-based strategies to prevent drug use and
mitigate injection-related harm. Although maintenance
therapy with methadone or buprenorphine is efﬁcacious
among adolescents and young adults,
40 41 challenges
remain in making these services accessible to street
youth, who are a marginalised and difﬁcult-to-reach
population.
42 43 Other effective harm reduction services
such as needle exchange and supervised safe injection
facilities are often developed for adult drug users and
may not effectively target younger drug users.
3 Barriers
to preventive and treatment modalities for young drug
users are well documented, and include excessively long
waiting lists, difﬁculty in complying with programme
rules, programme fees that exceed young people’s
ability to pay, and locations that are inconvenient for
youth.
42 Existing drug treatment and harm reduction
services should be extended in a way that is sensitive to
the unique circumstances of youth.
There are limitations to this study. First, as outlined
above, we acknowledge a relatively small proportion of
the sample who injected prescription opioids, which
may have affected the precision of our estimates.
Second, we employed snowball sampling in order to
recruit heavily drug-involved youth, who are frequently
homeless and represent a population ‘hidden’ from
traditional population-based sampling. Although snow-
ball sampling does not produce a truly random
sample,
24 it is noteworthy that the characteristics of the
ARYS cohort are similar to those of other at-risk youth
in western Canada.
44 45 A ﬁnal point regarding represen-
tativeness is the refusal rate among youth who are
approached for enrolment into the study. Unfortunately,
as youth often self-refer and street-based outreach often
requires a very low threshold approach commonly involv-
ing repeated contact, rates of refusal can only be esti-
mated. Study staff estimate that 30% of youth ﬁrst
approached for participation ultimately agree to be
assessed for eligibility. Third, our study relied on self-
report, which, as outlined above, may have resulted in
social desirability bias for questions probing sensitive
details. Finally, for polysubstance-using youth in the
sample, we cannot rule out that the risk for HCV in our
models attributed to heroin may have been better attrib-
uted to risky behaviours associated with injection of
other drugs. However, we sought to explore the inde-
pendent effects of other drugs in our modelling by
Table 2 Unadjusted and adjusted Cox proportional hazard analysis of time to hepatitis C infection among 512 drug-using
youth: At-Risk Youth Study (ARYS), Vancouver, British Columbia, 2005–2011
Characteristic
Adjusted HR (95% CI)
Unadjusted HR (95% CI) Model 1* Model 2† Model 3‡
Male gender 0.48 (0.28 to 0.81) 0.50 (0.28 to 0.90) 0.42 (0.24 to 0.75) 0.50 (0.28 to 0.90)
Age (per year older) 0.96 (0.87 to 1.06) 1.10 (0.91 to 1.10) 1.00 (0.91 to 1.11) 1.00 (0.91 to 1.10)
Prescription opioid injection 3.48 (1.57 to 7.70) – 2.02 (0.89 to 4.61) 0.94 (0.40 to 2.21)
Heroin injection 9.89 (5.72 to 17.1) 4.49 (2.42 to 8.33) – 4.56 (2.39 to 8.70)
Cocaine injection 5.69 (3.18 to 10.2) 1.87 (1.00 to 3.47) 2.20 (1.14 to 4.23) 1.88 (1.00 to 3.54)
Crystal methamphetamine injection 7.39 (4.36 to 12.5) 2.94 (1.62 to 5.34) 5.11 (2.79 to 9.34) 2.91 (1.57 to 5.38)
Syringe sharing 7.69 (3.93 to 15.0) 2.47 (1.20 to 5.09) 2.57 (1.24 to 5.32) 2.47 (1.20 to 5.10)
*Model 1 includes all covariates listed except prescription opioid injection.
†Model 2 includes all covariates listed except heroin injection.
‡Model 3 includes all covariates listed.
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Open Accesscontrolling for injection of the most common of other
substances of misuse.
In summary, we found that the risk for HCV acquisi-
tion among street youth in this setting was alarmingly
high, and that intravenous drug injection remains a
primary risk factor. Interestingly, although prescription
opioid misuse is on the rise in North America, in our
sample, the risk of HCV acquisition from injection of
prescription opioids did not exceed that of traditional
street drugs, including heroin, cocaine and crystal meth-
amphetamine. Nonetheless, prescription opioid injec-
tion should be the focus of further study to explore this
emerging and poorly understood practice. Given the
high prevalence and incidence of HCV seropositivity
among street youth, there is an urgent need for
evidence-based strategies, including educational pro-
gramming, addiction treatment and harm reduction ser-
vices, to prevent disease transmission in this vulnerable
population.
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